7b9625284b
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md - Domain: health - Claims: 0, Entities: 2 - Enrichments: 1 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
23 lines
No EOL
1 KiB
Markdown
23 lines
No EOL
1 KiB
Markdown
# Semaglutide for Cocaine Use Disorder in HIV Cohort (Phase 2)
|
|
|
|
**Type:** Clinical trial
|
|
**Phase:** 2
|
|
**Status:** Recruiting (as of May 2026)
|
|
**Intervention:** Semaglutide vs. placebo
|
|
**Population:** Adults with cocaine use disorder, with and without HIV infection
|
|
**Primary objective:** Safety and effectiveness of semaglutide for CUD
|
|
**Special population rationale:** High CUD prevalence in HIV+ individuals; dual metabolic and addiction benefits
|
|
**Registry:** withpower.com/trial/phase-2-human-immunodeficiency-virus-hiv-infections-2-2025
|
|
|
|
## Timeline
|
|
|
|
- **2025-02** — Trial opened for recruitment
|
|
- **2026-05** — Actively recruiting participants
|
|
|
|
## Context
|
|
|
|
This trial targets a high-need population where CUD prevalence is elevated and metabolic complications are common. The HIV-specific design provides real-world justification for off-label use even before CUD-specific approval. Follows All of Us observational signal (OR=0.25 for CUD in GLP-1 users).
|
|
|
|
## Expected Results
|
|
|
|
Phase 2 results anticipated 2027-2028. |